1 Revelli N,Villa M A,Olivero B,et al.A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions[J]. Vox Sang,2019,114(1):73-78.
2 Pavenski K,Freedman J,Semple J W.HLA alloimmunization against platelet transfusions:pathophysiology,significance,prevention and management[J]. Tissue Antigens,2012,79(4):237-245.
3 魏亚明,吕毅.基础输血学[M],人民卫生出版社,2011.1,280-282.
4 Elhence P,Chaudhary R K,Nityanand S.Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets[J]. Trasfusione Del Sangue,2014,12(2):180-186.
5 杨乾坤,陈李影慧. 多次输血患者血小板抗体检测与血小板输注疗效相关性研究[J]. 中国输血杂志,2017,30(12):1363-1365.
6 董宏伟. 探讨多次输血患者血小板抗体及血小板输注效果的影响[J]. 临床检验杂志(电子版),2019,8(4):132-133.
7 Bajpai M,Kaura B,Marwaha N,et al.Platelet alloimmunization in multitransfused patients with haemato-oncological disorders[J]. Natl Med J India,2005,18(3):134-136.
8 张秋会,胡兴斌,孙文利,等. 血小板抗体检测及配型在肿瘤患者中的临床应用[J]. 中国输血杂志,2016,29(7):708-710.
9 张燕. 血小板抗体检测对肿瘤患者血小板输注疗效的影响[J]. 泰山医学院学报,2018,39(3):303-305.
10 李拥军,李娜,唐家英,等. 红细胞血型抗体指标表达对安全输血的实验研究[J]. 中外医疗,2014,33(21):26-27.
11 郭文敬,刘燕明. 输血前抗体筛检临床意义分析[J]. 国际检验医学杂志,2012,33(24):3047-3048.
12 徐煜,吴林伯,吴芳,等. 血液病反复输血者血小板抗体对血小板输注效果的影响[J]. 河北医学,2016,22(6):931-933.
13 吴竹林,左祝华. 造血干细胞移植患者的输血治疗进展[J]. 透析与人工器官,2005,16(3):1-5.
14 Nielsen H S,Witvliet M D,Steffensen R,et al.The presence of HLA-antibodies in recurrent miscarriage patients is associated with a reduced chance of a live birth[J]. J Reprod Immunol,2010,87(1/2):67-73.
15 Abraham A S,Chacko M P,Fouzia N A,et al.Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions[J]. Transfusion Med,2018,28(5):392-397.
16 Vassallo R R.Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients[J]. Immunohematology,2009,25(3):119-124.
17 Kiefel V,König C,Kroll H,et al.Platelet alloantibodies in transfused patients[J]. Transfusion,2001,41(6):766-770.
18 Bertrand G,Drame M,Martageix C,et al.Response:Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia[J]. Blood,2011,117(11):3209-3213.
19 Peterson J A,McFarland J G,Curtis B R,et al. Neonatal alloimmune thrombocytopenia:pathogenesis,diagnosis and management[J]. Br J Haematol,2013,161(1):3-14.
20 Kamphuis M M,Paridaans N P,Porcelijn L,et al.Incidence and consequences of neonatal alloimmune thrombocytopenia:a systematic review[J]. Pediatrics,2014,133(4):715-721.
21 王培华. 输血技术学[M].人民卫生出版社,2002,182-183.
22 Bonstein L,Haddad N.Taking a wider view on fetal/neonatal alloimmune thrombocytopenia[J]. Thromb Res,2017,151(Suppl 1):S100-S102.
23 Killie M K,Husebekk A,Kjeldsen-Kragh J,et al.A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn[J]. Haematologica,2008,93(6):870-877.
24 Williamson L M,Hackett G,Rennie J,et al.The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1,Zwa) as determined by antenatal screening[J]. Blood,1998,92(7):2280-2287.
25 Brojer E,Husebekk A,Dębska M,et al.Fetal/neonatal alloimmune thrombocytopenia:pathogenesis,diagnostics and prevention[J]. Arch Immunol Ther Exp (Warsz),2016,64(4):279-290.
26 Menis M,Forshee R A,Anderson S A,et al.Posttransfusion Purpura occurrence and potential risk factors among the inpatient US elderly,as recorded in large Medicare databases during 2011 through 2012[J]. Transfusion,2015,55(2):284-295.
27 Metcalfe P.Platelet antigens and antibody detection[J]. Vox Sang,2004,87(Suppl1):82-86.
28 陈丽,周浩,郭博,等. 孕妇孕期血小板抗体检测的影响因素分析[J]. 中国输血杂志,2019,32(6):575-577.
29 谢仁伟,王明泉,李丽群,等. 孕晚期孕妇2038例血小板抗体筛查分析[J]. 福建医药杂志,2016,38(2):98-99.
30 Ding J W,Zhou T T,Zeng H S,et al.Hyperacute rejection by anti-Gal IgG1,IgG2a,and IgG2b is dependent on complement and Fc-Gamma receptors[J]. J Immunol,2008,180(1):261-268.
31 Li C L,Piran S,Chen P G,et al.The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies[J]. J Clin Invest,2011,121(11):4537-4547.
32 Yougbaré I,Lang S A,Yang H,et al.Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage[J]. J Clin Invest,2015,125(4):1545-1556.
33 苗新宇. 血小板相关抗体水平对特发性血小板减少性紫癜预后的价值研究[J]. 北方药学,2016,13(8):125-126.
34 古健,陈焯文. 血小板相关抗体检测在IPT诊断中的价值[J]. 中国热带医学,2012,12(1):82-83.
35 Hamidpour M,Khalili G,Tajic N,et al.Comparative of three methods (ELIZA,MAIPA and flow cytometry) to determine anti-platelet antibody in children with ITP[J]. Transfusion. 2015,55(2):284-295. |
